tiprankstipranks
Amplia Therapeutics Ltd. (AU:ATX)
ASX:ATX
Holding AU:ATX?
Track your performance easily

Amplia Therapeutics Ltd. (ATX) Share Price & Analysis

3 Followers

ATX Stock Chart & Stats


Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

4.36%95.64%
― Other Institutional Investors
95.64% Public Companies and
Individual Investors

ATX FAQ

What was Amplia Therapeutics Ltd.’s price range in the past 12 months?
Amplia Therapeutics Ltd. lowest share price was AU$0.05 and its highest was AU$0.17 in the past 12 months.
    What is Amplia Therapeutics Ltd.’s market cap?
    Currently, no data Available
    When is Amplia Therapeutics Ltd.’s upcoming earnings report date?
    Amplia Therapeutics Ltd.’s upcoming earnings report date is Jun 02, 2025 which is in 162 days.
      How were Amplia Therapeutics Ltd.’s earnings last quarter?
      Currently, no data Available
      Is Amplia Therapeutics Ltd. overvalued?
      According to Wall Street analysts Amplia Therapeutics Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Amplia Therapeutics Ltd. pay dividends?
        Amplia Therapeutics Ltd. does not currently pay dividends.
        What is Amplia Therapeutics Ltd.’s EPS estimate?
        Amplia Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Amplia Therapeutics Ltd. have?
        Amplia Therapeutics Ltd. has 385,126,600 shares outstanding.
          What happened to Amplia Therapeutics Ltd.’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Amplia Therapeutics Ltd.?
          Currently, no hedge funds are holding shares in AU:ATX
          ---

          Amplia Therapeutics Ltd. Stock Smart Score

          Company Description

          Amplia Therapeutics Ltd.

          Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.
          ---
          Similar Stocks
          Company
          Price & Change
          Follow
          Anixa Biosciences
          Immutep
          Cellectar Biosciences
          TG Therapeutics
          Amplia Therapeutics Ltd.
          Popular Stocks
          ---
          What am I Missing?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis